5.11

11.82% 0.54

After Hours: 5.06 -0.05 -0.98%

Zentalis Pharmaceuticals Inc (ZNTL)

Overview News Price History Option Chain Financials Why ZNTL Down? Discussions Forecast

Zentalis Pharmaceuticals Inc stock is traded at $5.11, with a volume of 3.55M. It is up +11.82% in the last 24 hours and up +41.16% over the past month. Zentalis Pharmaceuticals Inc is a clinical-stage biopharmaceutical company developing azenosertib (ZN-c3), a potentially first-in-class and best-in-class WEE1 inhibitor for patients with Cyclin E1-positive platinum-resistant ovarian cancer (Cyclin E1+ PROC). The Company manages its operations as a single segment for the purposes of assessing performance and making operating decisions.

Previous Close:

$4.57

Open:

$4.68

24h Volume:

3.55M

Relative Volume:

2.87

Market Cap:

$363.76M

Revenue:

$26.87M

Net Income/Loss:

$-124.13M

P/E Ratio:

-2.9405

EPS:

-1.7378

Net Cash Flow:

$-125.60M

1W Performance:

+4.71%

1M Performance:

+41.16%

6M Performance:

+72.64%

1Y Performance:

+254.86%

1-Day Range:

$4.68

$5.338

1-Week Range:

$4.39

$5.338

52-Week Range:

$1.212

$6.95

Zentalis Pharmaceuticals Inc Stock (ZNTL) Company Profile

Name

Zentalis Pharmaceuticals Inc

Sector

Healthcare (1092)

Industry

Biotechnology (603)

Phone

(858) 263-4333

Address

10275 SCIENCE CENTER DRIVE, SAN DIEGO, NY

Employee

106

Twitter

@ZentalisP

Next Earnings Date

2026-08-05

Latest SEC Filings

ZNTL's Discussions on Twitter

Compare ZNTL vs VRTX, REGN, ARGX, RVMD, ALNY

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
ZNTL Zentalis Pharmaceuticals Inc	5.11	325.32M	26.87M	-124.13M	-125.60M	-1.7378
VRTX Vertex Pharmaceuticals Inc	485.65	123.36B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	676.69	71.18B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	860.55	53.68B	4.16B	1.29B	734.26M	19.58
RVMD Revolution Medicines Inc	186.16	38.09B	742.00K	-1.37B	-1.07B	-7.0731
ALNY Alnylam Pharmaceuticals Inc	267.47	37.80B	4.29B	577.22M	641.34M	4.2086

Zentalis Pharmaceuticals Inc Stock (ZNTL) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Mar-17-26	Resumed	Wells Fargo	Equal Weight
Aug-12-24	Upgrade	Wedbush	Underperform → Neutral
Jun-20-24	Downgrade	UBS	Buy → Neutral
Jun-18-24	Downgrade	Jefferies	Buy → Hold
Jun-18-24	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jun-18-24	Downgrade	Wedbush	Neutral → Underperform
Jun-18-24	Downgrade	Wells Fargo	Overweight → Equal Weight
Nov-08-23	Downgrade	Wedbush	Outperform → Neutral
Nov-07-23	Downgrade	Leerink Partners	Outperform → Market Perform
Jul-12-22	Initiated	Cowen	Outperform
Apr-06-22	Initiated	Wells Fargo	Overweight
Oct-07-21	Resumed	Jefferies	Buy
Sep-30-21	Initiated	Stifel	Buy
Sep-29-21	Initiated	Oppenheimer	Outperform
May-21-21	Initiated	UBS	Buy
Jan-20-21	Initiated	Wedbush	Outperform
Sep-29-20	Initiated	Cantor Fitzgerald	Overweight
Aug-27-20	Initiated	H.C. Wainwright	Buy
Apr-28-20	Initiated	Guggenheim	Buy
Apr-28-20	Initiated	Jefferies	Buy
Apr-28-20	Initiated	Morgan Stanley	Overweight
Apr-28-20	Initiated	SVB Leerink	Outperform

View All

Zentalis Pharmaceuticals Inc Stock (ZNTL) Latest News

04:15 AM

Zentalis Pharmaceuticals to Present at the European Society for Medical Oncology (ESMO) Congress 2026 - GlobeNewswire

04:15 AM

Zentalis' Azenosertib Accepted for Rapid ESMO Survival Presentation - Stock Titan

04:15 AM

10:09 AM

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks Movin - Benzinga

10:09 AM

08:17 AM

Zentalis Pharmaceuticals Initiated at Outperform by Mizuho - Moomoo

08:17 AM

05:42 AM

Mizuho initiates Zentalis Pharmaceuticals stock at Outperform - Investing.com

05:42 AM

05:18 AM

Mizuho initiates Zentalis Pharmaceuticals stock at Outperform By Investing.com - Investing.com Canada

05:18 AM

Jul 13, 2026

ZNTL Stock Rallies To Near 22-Month Highs – An Analyst Sees Further 56% Upside After A Crucial Trial Update - Stocktwits

Jul 13, 2026

Jul 08, 2026

Zentalis Pharmaceuticals outlines its oncology focus as Nasdaq-listed biotech - Ad Hoc News

Jul 08, 2026

Zentalis Pharmaceuticals (ZNTL) Jefferies Global Life Sciences Conference Summary - Quartr

Jul 08, 2026

Jul 07, 2026

Zentalis Pharmaceuticals outlines oncology pipeline strategy as clinical programs advance - Ad Hoc News

Jul 07, 2026

Jul 06, 2026

ZNTL Q1 2026 Earnings: Slightly Wider Loss Meets Modest Stock UptickEarnings Quality Score - dars.gov.et

Jul 06, 2026

Jul 01, 2026

June 2026 Penny Stocks With Promising Potential - Sahm

Jul 01, 2026

Jun 29, 2026

Zentalis Pharmaceuticals Surges 14%: Biotech Stock Breaks Above Key Support ZoneBearish Pattern Stocks - dars.gov.et

Jun 29, 2026

Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 2000 Index - marketscreener.com

Jun 29, 2026

Zentalis Pharmaceuticals, Inc.(NasdaqGM: ZNTL) added to Russell 3000E Index - marketscreener.com

Jun 29, 2026

Jun 28, 2026

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Comp Value Benchmark - marketscreener.com

Jun 28, 2026

Zentalis Pharmaceuticals, Inc.(NasdaqGM:ZNTL) added to Russell Small Cap Completeness Index - marketscreener.com

Jun 28, 2026

Jun 26, 2026

ZNTL Q1 2026 Earnings: EPS Miss Weighs on Shares as Pipeline Progress Remains in FocusCost Structure Review - DonanımHaber

Jun 26, 2026

Jun 25, 2026

Zentalis Pharmaceuticals, Inc. Actuals & Estimates (NASDAQ:ZNTL) - TradingView

Jun 25, 2026

Jun 24, 2026

Enterprise value to revenue forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView

Jun 24, 2026

Price to book forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView

Jun 24, 2026

Price to sales forward of Zentalis Pharmaceuticals, Inc. – NASDAQ:ZNTL - TradingView

Jun 24, 2026

Jun 23, 2026